Document Classification

Section Type: RESULTS

Text: Compared with control subjects, participants receiving glargine : (i) were 1. 68 times more likely to achieve two consecutive HbA1c levels < or = 6. 5 % (95 % CI 1. 00-2. 83 ; P = 0. 049) ; (ii) reduced their HbA1c by 1. 55 vs. 1. 25 % (P = 0. 005), achieving adjusted means of 7. 0 vs. 7. 2 % (P = 0. 0007) ; (iii) had lower FPG (P = 0. 0001), non-high-density lipoprotein (HDL) cholesterol (P = 0. 02) and triglycerides (P = 0. 02) ; (iv) had greater increases in treatment satisfaction (P = 0. 045) ; and (v) had a 1. 9-kg greater increase in weight (P < 0. 0001).